Story perspectives

New GLP-1 Drugs: Weight Loss Gains vs. Nausea Risk

11/24/2025

24 3

Summary

Story summary

New research at Neuroscience 2025 shows GLP-1 weight-loss drugs affect appetite and nausea.
These medications, originally for type 2 diabetes, cause nausea in up to 40% of users.
Low-dose tirzepatide with oxytocin may boost weight loss and lessen GI issues.
GLP-1 receptor activation in specific brain regions can trigger weight loss and nausea.
A reward circuit influenced by GLP-1 drugs may affect eating and addiction, with implications for chronic conditions.

1 of 1

Story summary

New research at Neuroscience 2025 shows GLP-1 weight-loss drugs affect appetite and nausea.
These medications, originally for type 2 diabetes, cause nausea in up to 40% of users.
Low-dose tirzepatide with oxytocin may boost weight loss and lessen GI issues.
GLP-1 receptor activation in specific brain regions can trigger weight loss and nausea.
A reward circuit influenced by GLP-1 drugs may affect eating and addiction, with implications for chronic conditions.